JonesTrading Highlights Differentiated Pipeline at Atai Beckley N.V. (ATAI) [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
coverage on Atai Beckley N.V. (NASDAQ:ATAI) with a ‘Buy' rating and a price target of $16, according to TheFly. This translates to an upside potential of nearly 282%. According to the firm, the company's psychedelic and empathogenic drugs pipeline presents “differentiated opportunities” across large neuropsychiatric indications. Walsh believes Atai Beckley N.V. (NASDAQ:ATAI) will benefit from the ongoing trends supporting the development of drugs in these classes. The short half-lives of the company's BPL-003 and VLS-01 will “allow their use in treatment-resistant depression (TRD),” after Johnson & Johnson's SPRAVATO (esketamine) commercial approach. Dragon Images/Shutterstock.com While acknowledging the broad TRD market's potential to accommodate multiple successful therapies, JonesTrading noted the strength of the company's lead compounds, led by SPRAVATO. The analyst remains hopeful about the effectiveness of the company's third clinical asset, EMP-01, in social anxiety disor
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapiesBusiness Wire
- Notable healthcare headlines for the week: J&J, Pfizer, and Novo Nordisk in focus [Seeking Alpha]Seeking Alpha
- Johnson & Johnson Terminates Trial of Atopic Dermatitis Drug Candidate [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson halts mid-stage trial of experimental eczema drug [CNBC]CNBC
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website